CA2987744C — Psma-binding agents and uses thereof
Assigned to Johns Hopkins University · Expires 2022-11-15 · 4y expired
What this patent protects
Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof The compounds having the general formula below (see above formula) wherein Z is tetrazole or CO2Q; each Q is independently selected f…
USPTO Abstract
Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof The compounds having the general formula below (see above formula) wherein Z is tetrazole or CO2Q; each Q is independently selected from hydrogen or a protecting group; and wherein m is 0, 1, 2, 3, 4, 5, or 6; Y is a variety of groups or a covalent bond. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.